Market-Moving News for April 16th
Market-Moving News for April 16th
CGEM: 23% | Cullinan Therapeutics To Pursue Development Of CLN-978 In Autoimmune Diseases, With Systemic Lupus Erythematosus As First Indication; Discontinued Enrollment In Its B-NHL Study To Focus Ongoing Development On Autoimmune Indications
CGEM：23% | Cullinan Therapeutics 將繼續開發 CLN-978 用於自身免疫性疾病，以系統性紅斑狼瘡爲第一適應症；停止招收其 B-NHL 研究，將持續開發重點放在自身免疫適應症上
ITCI: 33% | Intra-Cellular Reports Phase 3 Topline Results From Study 501 Evaluating Lumateperone As Adjunctive Therapy In Patients With Major Depressive Disorder; Lumateperone 42 Mg Met The Primary Endpoint
ITCI：33% | 細胞內報告第501項研究評估盧馬佩龍作爲重度抑鬱症患者的輔助療法的第3階段結果；Lumateperone 42 mg達到主要終點
BRTX: 63% | BioRestorative Therapies shares are trading higher after the company announced FDA clearance of its Phase 2 BRTX-100 clinical study protocol amendment.
BRTX：63% | 生物修復療法公司宣佈美國食品藥品管理局批准其第二階段 BRTX-100 臨床研究方案修正案後，該公司股價走高。
譯文內容由第三人軟體翻譯。